Galectin Therapeutics Inc... (GALT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Galectin Therapeutics Statistics
Share Statistics
Galectin Therapeutics has 62.31M shares outstanding. The number of shares has increased by 0.74% in one year.
Shares Outstanding | 62.31M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.05% |
Owned by Institutions (%) | n/a |
Shares Floating | 43.22M |
Failed to Deliver (FTD) Shares | 30.91K |
FTD / Avg. Volume | 4.19% |
Short Selling Information
The latest short interest is 5.52M, so 8.85% of the outstanding shares have been sold short.
Short Interest | 5.52M |
Short % of Shares Out | 8.85% |
Short % of Float | 12.76% |
Short Ratio (days to cover) | 42.37 |
Valuation Ratios
The PE ratio is -2.43 and the forward PE ratio is -0.73.
PE Ratio | -2.43 |
Forward PE | -0.73 |
PS Ratio | 0 |
Forward PS | 0.4 |
PB Ratio | -1.66 |
P/FCF Ratio | -3.03 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Galectin Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of -1.19.
Current Ratio | 1.77 |
Quick Ratio | 1.77 |
Debt / Equity | -1.19 |
Total Debt / Capitalization | 620.85 |
Cash Flow / Debt | -0.46 |
Interest Coverage | -14.86 |
Financial Efficiency
Return on equity (ROE) is 0.68% and return on capital (ROIC) is -329.17%.
Return on Equity (ROE) | 0.68% |
Return on Assets (ROA) | -1.46% |
Return on Capital (ROIC) | -329.17% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.93M |
Employee Count | 14 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -27.81% in the last 52 weeks. The beta is 0.63, so Galectin Therapeutics 's price volatility has been higher than the market average.
Beta | 0.63 |
52-Week Price Change | -27.81% |
50-Day Moving Average | 1.79 |
200-Day Moving Average | 2.47 |
Relative Strength Index (RSI) | 40.72 |
Average Volume (20 Days) | 738.49K |
Income Statement
Revenue | n/a |
Gross Profit | -33.00K |
Operating Income | -38.07M |
Net Income | -41.07M |
EBITDA | -202.00K |
EBIT | n/a |
Earnings Per Share (EPS) | -0.74 |
Balance Sheet
The company has 25.66M in cash and 71.81M in debt, giving a net cash position of -46.15M.
Cash & Cash Equivalents | 25.66M |
Total Debt | 71.81M |
Net Cash | -46.15M |
Retained Earnings | -354.37M |
Total Assets | 28.97M |
Working Capital | 3.41M |
Cash Flow
In the last 12 months, operating cash flow was -32.97M and capital expenditures 0, giving a free cash flow of -32.97M.
Operating Cash Flow | -32.97M |
Capital Expenditures | 0 |
Free Cash Flow | -32.97M |
FCF Per Share | -0.55 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GALT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -60.66% |
FCF Yield | -43.37% |
Analyst Forecast
The average price target for GALT is $11, which is 801.6% higher than the current price. The consensus rating is "Buy".
Price Target | $11 |
Price Target Difference | 801.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Mar 23, 2012. It was a backward split with a ratio of 1:6.
Last Split Date | Mar 23, 2012 |
Split Type | backward |
Split Ratio | 1:6 |
Scores
Altman Z-Score | -22.91 |
Piotroski F-Score | 2 |